Hypertension in pregnant women: a view from the perspective of the European recommendations 2018

The problem of arterial hypertension (HTN) in pregnant women is very important due to its high prevalence and severity of consequences for the mother and fetus. In Russia, hypertension is diagnosed in 5–30% pregnant women, with the increasing trend in the past decades. HTN is a risk factor for complications, both for the mother, the fetus and newborn, so HTN remains the leading cause of maternal, fetal and neonatal mortality. HTN in pregnant women is a signifcant predictor of cardiovascular disease in the future. It is also a social problem considering the increase in the cost of treatment, i.e. related to the repeated hospitalizations after childbirth. In 2018, new European recommendations on cardiovascular diseases during pregnancy and European recommendations on HTN (the latter ones include special sections devoted to hypertension in pregnant women) were published. These recommendations provide the latest data on the classifcation, diagnosis and treatment of HTN in pregnant women. Currently, methyldopa is still the frst-line drug for the treatment of HTN in pregnant women, which has proved to be an effective and safe medication in pregnant women.

1. Clinical recommendations. Arterial hypertension in pregnant women. 2016. https://medi.ru/klinicheskie-rekomendatsii/arterialnaya-gipertoniyau-beremennykh_13865. In Russian.

2. Manuhin IB, Markova EV, Markova LI, Stryuk RI. Combined low-dose antihypertensive therapy in pregnant women with arterial hypertension and gestosis. Kardiologiia. 2012;52(1):32–38. In Russian.

3. Kirsanova TV, Mikhailova OI. Principles of treatment of arterial hypertension during pregnancy. Russian Medical Journal. 2012;21: 1097. In Russian.

4. Vertkin AL, Tkacheva ON, Murashko LE, Tumbaev IV, Mishina IE. Arterial hypertension of pregnant women: diagnosis, management tactics and approaches to treatment. Lechashchij Vrach = The Physician. 2006;3:25–8. In Russian.

5. Madi JM, Araújo BF, Zatti H, Rombaldi RL, Madi SR, de Zorzi P et al. Chronic hypertension and pregnancy at a tertiary-care and university hospital. Hypertens Pregnancy. 2012;31(3):350–356. doi:10.3109/10641955.2010.525279

6. Magee LA, von Dadelszen P, Singer J, Lee T, Rey E, Ross S, CHIPS Study Group. The CHIPS Randomized Controlled Trial (Control of Hypertensionin Pregnancy Study): Is Severe Hypertension Just an Elevated Blood Pressure? Hypertension. 2016;68(5):1153– 1159. doi:10.1161/HYPERTENSIONAHA.116.07862

7. Tooher J, Thornton C, Makris A, Ogle R, Korda A, Hennessy A. All hypertensive disorders of pregnancy increase the risk of future cardiovascular disease. Annals of Internal Medicine. 2018;169(4):224–232. doi:10.7326/M17-2740

8. Stuart JJ, Tanz LJ, Missmer SA, Rimm EB, Spiegelman D, James-Todd TM et al. Hypertensive disorders of pregnancy and maternal cardiovascular disease risk factor development: an observational cohort study. Ann Intern Med. 2018;169(4):224–232. doi:10.7326/M17–2740

9. Mulubrhan F, Salemi JL, Spooner KK, McFarlin BL, Salihu HH. Hypertensive disorders of pregnancy and postpartum readmissionin the United States: national surveillance of the revolving door Mogos. J Hypertens. 2018;36(3):608–618. doi:10.1097/HJH.0000000000001594

10. 2018 ESC Guidelines for the management of cardiovascular disease during pregnancy. Eur Heart J. 2018; 39(34):3165–3241. doi:10.1093/eurheartj/ehy340

11. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39(33):3021–3104. doi:10.1093/eurheartj/ehy339

12. Villar J, Carroli G, Wojdyla D, Abalos E, Giordano D, Ba’aqeel H et al. Preeclampsia, gestational hypertension and intrauterine growth restriction, related or independent conditions? Am J Obstet Gynecol. 2006;194(4):921–931. doi:10.1016/j.ajog.2005.10.813

13. Penny JA, Halligan AW, Shennan AH, Lambert PC, Jones DR, de Swiet M et al. Automated, ambulatory, or conventional blood pressure measurement in pregnancy: which is the better predictor of severe hypertension? Am J Obstet Gynecol. 1998;178(3):521–526.

14. Magee LA, Ramsay G, von Dadelszen P. What is the role of out-of-offce BP measurement in hypertensive pregnancy? Hypertens Pregnancy 2008;27(2):95–101. doi:10.1080/10641950801950197

15. Schmella MJ, Clifton RG, Althouse AD, Roberts JM. Uric acid determination in gestational hypertension: Is it as effective a delineator of risk as proteinuria in high-risk women? Reprod Sci. 2015;22(10):1212–1219. doi:10.1177/1933719115572477

16. Cade TJ, de Crespigny PC, Nguyen T, Cade JR, Umstad MP. Should the spot albumin-to-creatinine ratio replace the spot proteinto-creatinine ratio as the primary screening tool for proteinuria in pregnancy? Pregnancy Hypertens. 2015;5(4):298–302. doi:10.1016/j.preghy.2015.07.001

17. Chappell LC, Shennan AH. Assessment of proteinuria in pregnancy. BMJ 2008;336(7651):968–969. doi:10.1136/bmj.39540.657928.BE

18. Cote AM, Firoz T, Mattman A, Lam EM, von Dadelszen P, Magee LA. The 24hour urine collection: gold standard or historical practice? Am J Obstet Gynecol. 2008;199(6):621–626. doi:10.1016/j.ajog.2008.06.009

19. Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennstrom M et al. Predictive value of the sFlt-1: PIGF ratio in women with suspected preeclampsia. N Engl J Med. 2016;374 (1):13–22. doi:10.1056/NEJMoa1414838

20. Leanos-Miranda A, Campos-Galicia I, Isordia-Salas I, Rivera-Leanos R, RomeroArauz JF, Ayala-Mendez JA et al. Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated ele ctrochemiluminescence immunoassays methods are predictors of preeclampsia. J Hypertens. 2012;30(11):2173–2181. doi:10.1097/HJH.0b013e328357c0c9

21. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M et al; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology. J Hypertens. 2013;31(10):1281–1357. doi:10.3109/08037051.2014.868629

22. American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122 (5):1122–1131. doi:10.1097/01.AOG.0000437382.03963.88

23. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Pregnancy Hypertens. 2014;4(2):105–145. doi:10.1016/j.preghy.2014.01.003

24. Lowe SA, Bowyer L, Lust K, McMahon LP, Morton MR, North RA et al. The somanz guidelines for the management of hypertensive disorders of pregnancy 2014. Aust N Z J Obstet Gynaecol. 2015;55(5):11–16. doi:10.1111/ajo.12253

25. Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, Cifkova R, Ferreira R, Foidart JM et al. ESC guidelines on the management of cardiovascular diseases during pregnancy. Eur Heart J. 2011;32(24):3147–3197. doi:10.1093/eurheartj/ehr218

26. National Collaborating Centre for Women’s and Children’s Health (UK). Hypertension in pregnancy: The management of hypertensive disorders during pregnancy. London: RCOG Press; 2010.

27. Rolnik DL, Wright D, Poon LC, O’Gorman N, Syngelaki A, de Paco Matallana C et al. Aspirin versus placebo in pregnancies at high-risk for preterm preeclampsia. N Engl J Med. 2017;377 (7):613–622. doi:10.1056/NEJMoa1704559

28. Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L, Torloni MR. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2014;6. doi:10.1002/14651858.CD001059.pub4

29. Xu H, Perez-Cuevas R, Xiong X, Reyes H, Roy C, Julien P et al. An international trial of antioxidants in the prevention of preeclampsia (INTAPP). Am J Obstet Gynecol. 2010;202(3):239. e1–239.e10. doi:10.1016/j.ajog.2010.01.050

30. Villar J, Purwar M, Merialdi M, Zavaleta N, Thi Nhu Ngoc N, Anthony J et al. World Health Organisation multicentre randomised trial of supplementation with vitamins C and E among pregnant women at high-risk for pre-eclampsia in populations of low nutritional status from developing countries. BJOG. 2009;116 (6):780–788. doi:10.1111/j.1471–0528.2009.02158.x

31. Spinnato JA II, Freire S, Pinto ESJL, Cunha Rudge MV, Martins-Costa S, Koch MA et al. Antioxidant therapy to prevent preeclampsia: a randomized controlled trial. Obstet Gynecol. 2007;110 (6):1311–1318. doi:10.1097/01.AOG.0000289576.43441.1f.

32. Poston L, Briley AL, Seed PT, Kelly FJ, Shennan AH. Vitamin C and vitamin E in pregnant women at risk for preeclampsia (VIP trial): Randomised placebocontrolled trial. Lancet. 2006;367(9517):1145–1154. doi:10.1016/S0140-6736(06)68 433-X

33. Redman CW. Fetal outcome in trial of antihypertensive treatment in pregnancy. Lancet. 1976;2(7989):753–756.

34. Cockburn J, Moar VA, Ounsted M, Redman CW. Final report of study on hypertension during pregnancy: The effects of specifc treatment on the growth and development of the children. Lancet. 1982;1(8273):647–649.

35. Dodd JM, Turnbull D, McPhee AJ, Deussen AR, Grivell RM, Yelland LN et al. Antenatal lifestyle advice for women who are overweight or obese: LIMIT randomised trial. BMJ. 2014;348:1285. doi:10.1136/bmj.g1285

36. Leddy MA, Power ML, Schulkin J. The impact of maternal obesity on maternal and fetal health. Rev Obstet Gynecol. 2008;1 (4):170–178.

37. Abalos E, Duley L, Steyn DW, Gialdini C. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2014;2: CD002252. doi:10.1002/14651858.CD002252.pub3

38. Shekhar S, Gupta N, Kirubakaran R, Pareek P. Oral nifedipine versus intravenous labetalol for severe hypertension during pregnancy: a systematic review and meta-analysis. BJOG. 2016;123(1):40–47. doi:10.1111/1471-0528.13463

39. Clark SM, Dunn HE, Hankins GD. A review of oral labetalol and nifedipine in mild to moderate hypertension in pregnancy. Semin Perinatol. 2015;39(7):548–555. doi:10.1053/j.semperi.2015.08.011

40. Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J et al. Do women with pre-eclampsia, and their babies, beneft from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet. 2002;359(9321):1877–1890.

41. Koopmans CM, Bijlenga D, Groen H, Vijgen SM, Aarnoudse JG, Bekedam DJ et al; HYPITAT study group. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks’ gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet. 2009;374(9694):979–988. doi:10.1016/S0140-6736(09)60736-4

42. Hilfker-Kleiner D, Haghikia A, Nonhoff J, Bauersachs J. Peripartum cardiomyopathy: current management and future perspectives. Eur Heart J. 2015;36(18):1090–1097. doi:10.1093/eurheartj/ehv009

43. Beardmore KS, Morris JM, Gallery ED. Excretion of antihypertensive medication into human breast milk: a systematic review. Hypertens Pregnancy. 2002;21(1):85–95. doi:10.1081/PRG-120002912

44. Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet. 2005;366(9499):1797–1803. doi:10.1016/S0140-6736(05)67726–4

45. Black MH, Zhou H, Sacks DA, Dublin S, Lawrence JM, Harrison TN et al. Hypertensive disorders first identified in pregnancy increase risk for incident prehypertension and hypertension in the year after delivery. J Hypertens. 2016;34 (4):728–735. doi:10.1097/HJH.0000000000000855

46. Sibai BM, Mabie WC, Shamsa F, Villar MA, Anderson GD. A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am J Obstet Gynecol. 1990;162(4):960–966; discussion 966.

47. Weitz C, Khouzami V, Maxwell K, Johnson JW. Treatment of hypertension in pregnancy with methyldopa: a randomized double blind study. Int J Gynaecol Obstet. 1987;25(1):35–40.

48. Briggs GG, Freeman RK. Drugs in Pregnancy and Lactation. Philadelphia: Lippincott Williams & Wilkins; 2014, 231 р.

49. de Jonge L, Zetstra-van der Woude PA, Bos HJ, de Jongvan den Berg LT, Bakker MK. Identifying associations between maternal medication use and birth defects using a case-population approach: an exploratorystudy on signal detection. Drug Saf. 2013;36(11):1069–1078. doi:10.1007/s40264-013-0082-2

50. Hoeltzenbein M, Beck E, Fietz AK, Wernicke J, Zinke S, Kayser A et al. Pregnancy outcome after frst trimester use of methyldopa a prospective cohort study. Hypertension. 2017;70 (1):201–208. doi:10.1161/HYPERTENSIONAHA.117.09110